Brief: Relmada Therapeutics Announces Top-Line Results From Phase 3 Reliance III Trial For Rel-1017 As A Monotherapy For The Treatment Of Major Depressive Disorder

Relmada Therapeutics

13/10/2022 12:14

Oct 13 (Reuters) - Relmada Therapeutics Inc  RLMD.O :
    * RELMADA THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM 
PHASE 3
RELIANCE III TRIAL FOR REL-1017 AS A MONOTHERAPY FOR THE
TREATMENT OF MAJOR DEPRESSIVE DISORDER
    * RELIANCE I AND II ADJUNCTIVE MDD TRIALS CONTINUE TO
ADVANCE
    * THERE WERE NO ADVERSE EVENTS RELATED TO QTCF PROLONGATION
    * REL-1017-303, EVALUATING REL-1017 IN MONOTHERAPY SETTING
FOR
MAJOR DEPRESSIVE DISORDER (MDD), DID NOT ACHIEVE ITS PRIMARY
ENDPOINT,
    * REL-1017 TREATMENT ARM SHOWED A MADRS REDUCTION OF 14.8
POINTS
AT DAY 28 VERSUS 13.9 POINTS FOR PLACEBO ARM
    * PARADOXICAL RESULTS WERE OBSERVED IN CERTAIN STUDY SITES,
WHERE
PLACEBO DRAMATICALLY OUTPERFORMED REL-1017
    * RELMADA IS INVESTIGATING NATURE OF RESULTS.

Source text for Eikon:  ID:nPnbMyH5Ha 
Further company coverage:  RLMD.O